December 2, 2022
View Archives Issues
In a well-controlled retrospective analysis of patients who presented with metastatic colorectal cancer, primary tumor resection was associated with improved overall survival.
For patients with BRCA-associated breast cancer, it had been previously demonstrated that a second breast cancer occurs in approximately one-third of patients by 15 years after diagnosis, and that this risk was reduced significantly by contralateral mastectomy.
In a multicenter, randomized, double-blind, placebo-controlled clinical trial of bevacizumab added to standard temozolomide and radiation therapy for patients with glioblastoma multiforme, progression-free survival but not overall survival was enhanced.
Bevacizumab added to chemotherapy, particularly paclitaxel and cisplatin, was efficacious in all response outcomes (objective response, progression-free survival, and overall survival) without diminution in quality of life or unacceptable toxicity.